DMTTF - Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business | Benzinga
Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc. (NYSE: CYBN), published its interim financial results for Q2 ended August 31, 2023.
Numbers showed:
-
Cash of $5.6 (CA$7.68) million by August 31, vs. $13.5 million held by Feb. 28, 2023, a 58.6% six-month burn rate. And an almost 72% YoY decrease considering August 31, 2022’s $19.8 million held in cash.
-
Six-month cash used in operating activities was $8.3 million vs. $8.98 million in the same comparable period in 2022.
-
Total non-operating expenses of $4.4 million and $8.6 million for three and six months of 2023, vs. $5.4 million and $9.7 million for the same periods in 2022.
-
Of those, R&D expenses totaled $1.67 million and $3.49 million for the three and six month periods ended August 31, ...